SARS-CoV-2 Spike Mutants
Recombinant antigens and lentivirus for emerging SARS-CoV-2 variants
During the course of COVID-19 pandemic, several new SARS-CoV-2 variants have emerged, each with differing mutations that can have impacts on transmissibility, COVID-19 disease severity, and effectiveness of vaccines. AMSBIO now offers a series of recombinant antigens and pseudotyped lentivirus with key Spike mutations in order to evaluate the efficacy of antibodies and vaccines. These products form part of our larger COVID-19 Tools for Research portfolio, including other high quality recombinant proteins, Spike pseudotyped lentivirus, and reagents for vaccine development and evaluation.
Features
-
Recombinant antigens from B.1.1.529, B.1.1.7,B.1.351, P.1, and B.1.617.2 SARS-CoV-2 mutants
- A range of other recombinant antigens with other key mutations
- SARS-CoV-2 Spike protein mutants pseudotyped lentivirus
- Custom lentivirus service for production of other Spike mutant pseudovirions
Applications
- Antibody and vaccination efficacy evaluation
- Studying the mechanism of viral transduction
- Screening for neutralizing antibodies for SARS-CoV-2 Spike and ACE2
Spike Mutant Recombinant Proteins
B.1.1.7, P.1, and B.1.617.2, B.1.351 and B.1.1.529 Variants
The B.1.1.7 variant strain (Alpha variant) of SARS-CoV-2 was first discovered in the United Kingdom in late 2020 with an unusually large number of mutations, including a 69/70 deletion and P681H. Following this, the variant has been detected in multiple countries around the world, including the United States, and is associated with increased transmissibility.
In South Africa, another variant of SARS-CoV-2 (Beta variant or B.1.351 lineage) emerged independently of the B.1.1.7 variant. This variant shares some mutations with the B.1.1.7 lineage, but does not contain the deletion at 69/70.
The P.1 variant (Gamma variant) was first identified in Japan, and it has originated in Brazil. This variant has 17 amino acid substitutions, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T.
In India, B.1.617.2 or Delta variant has been detected in late 2020. It has mutations in the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus.
In November 2021, the B.1.1.529 Omicron variant was reported to WHO from South Africa. Research shows this variant has a large number of mutations and preliminary evidence suggests an increased risk of reinfection with this variant, compared to other variants of concern.
We now provide B.1.1.7, P.1, B.1.617.2 , B.1.351, B.1.1.529Â lineages and other variants of interest SARS-CoV-2 Spike recombinant antigens for COVID-19 research.
| Name | Packsize | Order |
|---|
| Name | Packsize | Order |
|---|
| Name | Packsize | Order |
|---|
| Name | Packsize | Order |
|---|
Product Information Table
| Name | Packsize | Order |
|---|
| Name | Packsize | Order |
|---|
Nucleocapsid Protein Mutants
| Name | Packsize | Order |
|---|
Assay Kits
| Name | Packsize | Order |
|---|
Neutralizing Antibodies
| Name | Packsize | Order |
|---|
Spike Mutant Pseudotyped Lentivirus
To understand the mechanism of SARS-CoV-2 cell entry, it is essential to study how Spike proteins interact with the ACE2 receptor. However, such studies are hampered by the danger of producing and manipulating live coronavirus. A safer alternative to using live coronavirus is to use recombinant lentivirus pseudotyped with the coronavirus S protein. The Spike pseudotyped lentivirus includes a luciferase or EGFP reporter, allowing the monitoring of viral entry into host cells.
We provide ready-to-use SARS-CoV-2 Spike Pseudotyped Lentivirus for alpha, beta, gamma, and delta variants and D614G mutation. The D614G  mutation emerged in a variant of SARS-CoV-2 in late January or early February 2020 and was discovered to dramatically increase infectivity of the virus. These lentivirus produced with different SARS-CoV-2 Spike mutants as the envelope glycoproteins instead of the commonly used VSV-G, can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility. For further information on our other SARS-CoV-2 Spike Pseudotyped Lentiviruses, refer to this page.
| Name | Packsize | Order |
|---|
